Skip to main content

Novartis’ Sandoz acquires U.S. rights for Adamis’ EpiPen alternative

Adamis Pharmaceuticals has entered into an exclusive distribution and commercialization agreement with Swiss drug company Novartis’ Sandoz division to commercialize Adamis’ Symjepi for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Symjepi contains epinephrine, the same active ingredient as Mylan’s EpiPen.

Adamis said it expects Symjepi, which is available in a prefilled syringe, will be a cheaper alternative to Mylan’s generic version of EpiPen which comes in an auto-injector device.

Sandoz will have commercial rights to the FDA-approved Symjepi (epinephrine) injection 0.3 mg product, as well as the Symjepi (epinephrine) Injection 0.15 mg product if approved by the FDA. Adamis will retain the right to commercialize both products in territories outside of the United States but has granted Sandoz the first right of negotiation for such territories.

“We are very excited about our collaboration with Sandoz.  They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi,” said Adamis president and CEO Dr. Dennis J. Carlo. “We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.”

This ad will auto-close in 10 seconds